Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Fiche publication

Date publication

février 2025

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain , Pr BORG Christophe , Dr LADOIRE Sylvain , Dr CURTIT Elsa , Dr MANSI Laura , Dr DERANGERE Valentin , Dr LOYON Romain , Dr KROEMER Marie

Tous les auteurs :
Lopez M, Spehner L, André F, Viot J, Seffar E, Marguier A, Curtit E, Meynard G, Dobi E, Ladoire S, Boidot R, Loyon R, Derangere V, Bidard FC, Borg C, Mansi L, Kroemer M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39920833

Résumé

Breast Cancer (BC) is the most common type of cancer in women around the world and 70% of cases are hormone-receptor positive (HR+). In 40% of cases, a key mechanism of endocrine resistance to the standard first line is a mutation of the ligand-binding domain (LBD) of Estrogen Receptor 1 (ESR1) encoding estrogen receptor α (ER). Most common ESR1 mutations that occur at positions 537 and 538 have been associated with poor clinical outcomes. ESR1 mutations have the potential to provide neoantigens. This study aims to identify if ESR1 mutations generate specific T cell responses against ESR1 neoantigens in patients with HR HER2 BC, and to investigate if ESR1 mutations might correlate with a gene expression profile related to immune surveillance disruption.